Authors: Aladdin, H Larsen, CS Schjerling, P Moller, BK Buhl, MR Gerstoft, J Pedersen, BK Ullum, H

Citation: H. Aladdin et al., Effects of subcutaneous IL-2 therapy on telomere lengths in PBMC in HIV-infected patients, SC J IMMUN, 53(3), 2001, pp. 315-319

Authors: Molle, I Christensen, KL Hansen, PS Dragsted, UB Aarup, M Buhl, MR

Citation: I. Molle et al., Use of medical chemoprophylaxis and antimosquito precautions in Danish malaria patients and their traveling companions, J TRAVEL M, 7(5), 2000, pp. 253-258

Authors: Aladdin, H Larsen, CS Moller, BK Ullum, H Buhl, MR Gerstoft, J Skinhoj, P Pedersen, BK

Citation: H. Aladdin et al., Effects of subcutaneous interleukin-2 therapy on phenotype and function ofperipheral blood mononuclear cells in human immunodeficiency virus infected patients, SC J IMMUN, 51(2), 2000, pp. 168-175

Authors: Larsen, CS Ostergard, L Moller, BK Buhl, MR

Citation: Cs. Larsen et al., Subcutaneous interleukin-2 in combination with anti-retroviral therapy fortreatment of HIV-1-infected subjects, SC J IN DIS, 32(2), 2000, pp. 153-160

Authors: Molle, I Petersen, E Buhl, MR

Citation: I. Molle et al., Retrospective evaluation of exposure to P-falciparum using antibodies to circumsporozoite protein and to cultured P-falciparum antigens, SC J IN DIS, 31(1), 1999, pp. 69-71